Since ages, Anticholinergics (ACs)used to be one of the mainstay in the management of PD and I remember when we started treating PD patients initially, trihexphenidyl was never neglected in the prescription because of its benefits in tremors, urinary urgency, drooling and even in sleep disturbances, as associations in PD. As time pass by, the practic parameters have changed a lot to the extent of overusing dopamine agonists single or in combinations as well MAO inhibitors and in this process, ACs are getting faded away slowly because of the hype about potential short as well long-term side effects. Shelly gray's recent paper on a 7 yr follow up of patients on ACs reiterated the higher risk of dementia of more than 50% who were on ACs.
Should we throw out ACs from the armamentarium of PD pharmacotherapy, for ever? The bottom line for Parkinson’s disease patients is that there should…
